Development of a stable low-dose aglycosylated antibody formulation to minimize protein loss during intravenous administration

References

• Geigert J. Overview of the stability and handling of recombinant protein drugs. J Parenter Sci Technol 1989; 43:220-224; PMID:2809930
   PubMedGoogle Scholar
• Pinholt C, Hartvig RA, Medlicott NJ, Jorgensen L. The importance of interfaces in protein drug delivery - Why is protein adsorption of interest in pharmaceutical formulations? Expert Opin Drug Deliv 2011; 8:949-964; PMID:21557707; http://dx.doi.org/10.1517/17425247.2011.577062
   PubMed Web of Science ®Google Scholar
• Burke CJ, Steadman BL, Volkin DB, Tsai PK, Bruner MW, Middaugh CR. The adsorption of proteins to pharmaceutical container surfaces. Int J Pharm 1992; 86:89-93; http://dx.doi.org/10.1016/0378-5173(92)90034-Y
   Web of Science ®Google Scholar
• Patel JP, Tran LT, Sinai WJ, Carr LJ. Activity of urokinase diluted in 0.9% sodium chloride injection or 5% dextrose injection and stored in glass or plastic syringes. Am J Hosp Pharm 1991; 48:1511-1514; PMID:1882883
   PubMedGoogle Scholar
• Semba CP, Weck S, Patapoff T. Alteplase: Stability and bioactivity after dilution in normal saline solution. J Vasc Interv Radiol 2003; 14:99-102; PMID:12525593; http://dx.doi.org/10.1097/01.RVI.0000052297.26939.05
   PubMed Web of Science ®Google Scholar
• Semba CP, Weck S, Razavi MK, Tuomi L, Patapoff T. Tenecteplase: Stability and bioactivity of thawed or diluted solutions used in peripheral thrombolysis. J Vasc Interv Radiol 2003; 14:475-479; PMID:12682204; http://dx.doi.org/10.1097/01.RVI.0000064843.87207.F7
   PubMed Web of Science ®Google Scholar
• Tzannis ST, Hrushesky WJM, Wood PA, Przybycien TM. Adsorption of a formulated protein on a drug delivery device surface. J Colloid and Interface Sci 1997; 189:216-228; http://dx.doi.org/10.1006/jcis.1997.4841
   Web of Science ®Google Scholar
• Zahid N, Taylor KMG, Gill H, Maguire F, Shulman R. Adsorption of insulin onto infusion sets used in adult intensive care unit and neonatal care settings. Diabetes Res Clin Practice 2008; 80:11-13; PMID:18395926; http://dx.doi.org/10.1016/j.diabres.2008.02.013
   PubMedGoogle Scholar
• Parshuram CS, Ng GY, Ho TK, Klein J, Moore AM, Bohn D, Koren G. Discrepancies between ordered and delivered concentrations of opiate infusions in critical care. Crit Care Med 2003; 31:2483-2487; PMID:14530755; http://dx.doi.org/10.1097/01.CCM.0000089638.83803.B2
   PubMed Web of Science ®Google Scholar
• Parshuram CS, To T, Seto W, Trope A, Koren G, Laupacis A. Systematic evaluation of errors occurring during the preparation of intravenous medication. CMAJ 2008; 178:42-48; PMID:18166730; http://dx.doi.org/10.1503/cmaj.061743
   PubMed Web of Science ®Google Scholar
• The United States Pharmacopeial Convention 1999. Chapter <797> Pharmaceutical Compounding—Sterile Preparations. United States Pharmacopeia, Rockville, MD.
   Google Scholar
• Bardin C, Astier A, Vulto A, Sewell G, Vigneron J, Trittler R, Daouphars M, Paul M, Trojniak M, Pinguet F. Guidelines for the practical stability studies of anticancer drugs: A european consensus conference. Euro J Hosp Pharm Sci Pra 2012; 19:278-285
   Web of Science ®Google Scholar
• Beer PM, Wong SJ, Schartman JP, Kulas KE, Hartman CL, Giganti M, Falk NS. Infliximab stability after reconstitution, dilution, and storage under refrigeration. Retina 2010; 30:81-84; PMID:20010324; http://dx.doi.org/10.1097/IAE.0b013e3181b48fb4
   PubMed Web of Science ®Google Scholar
• Kumru OS, Liu J, Ji JA, Cheng W, Wang J, Wang T, Joshi SB, Middaugh CR, Volkin DB. Compatibility, physical stability, and characterization of an IgG4 monoclonal antibody after dilution into different intravenous administration bags. J Pharm Sci 2012; 101:3636-3650; PMID:22733600; http://dx.doi.org/10.1002/jps.23224
   PubMed Web of Science ®Google Scholar
• Kwong Glover ZW, Gennaro L, Yadav S, Demeule B, Wong PY, Sreedhara A. Compatibility and stability of pertuzumab and trastuzumab admixtures in i.v. infusion bags for coadministration. J Pharm Sci 2012; 102:794-812; PMID:23225178; http://dx.doi.org/10.1002/jps.23403
   PubMed Web of Science ®Google Scholar
• Paul M, Vieillard V, Jaccoulet E, Astier A. Long-term stability of diluted solutions of the monoclonal antibody rituximab. Int J Pharm 2012; 436:282-290; PMID:22789912; http://dx.doi.org/10.1016/j.ijpharm.2012.06.063
   PubMed Web of Science ®Google Scholar
• Sreedhara A, Glover ZK, Piros N, Xiao N, Patel A, Kebakoff B. Stability of IgG1 monoclonal antibodies in intravenous infusion bags under clinical in-use conditions. J Pharm Sci 2012; 101:21-30; PMID:21905032; http://dx.doi.org/10.1002/jps.22739
   PubMed Web of Science ®Google Scholar
• Pandey M, Mahadevan D. Monoclonal antibodies as therapeutics in human malignancies. Future Oncol 2014; 10:609-636; PMID:24754592; http://dx.doi.org/10.2217/fon.13.197
   PubMed Web of Science ®Google Scholar
• Buss NAPS, Henderson SJ, McFarlane M, Shenton JM, De Haan L. Monoclonal antibody therapeutics: History and future. Curr Opin Pharmacol 2012; 12:615-622; PMID:22920732; http://dx.doi.org/10.1016/j.coph.2012.08.001
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibodies to watch in 2015. mAbs 2015; 7:1-8; PMID:25484055; http://dx.doi.org/10.4161/19420862.2015.988944
   PubMed Web of Science ®Google Scholar
• Berek JS. Immunotherapy of ovarian cancer with antibodies: A focus on oregovomab. Expert Opin Biol Ther 2004; 4:1159-1165; PMID:15268682; http://dx.doi.org/10.1517/14712598.4.7.1159
   PubMed Web of Science ®Google Scholar
• Daugherty AL, Mrsny RJ. Formulation and delivery issues for monoclonal antibody therapeutics. Adv Drug Deliv Rev 2006; 58:686-706; PMID:16839640; http://dx.doi.org/10.1016/j.addr.2006.03.011
   PubMed Web of Science ®Google Scholar
• Ikesue H, Vermeulen LC, Hoke R, Kolesar JM. Stability of cetuximab and panitumumab in glass vials and polyvinyl chloride bags. Am J Health Syst Pharm 2010; 67:223-226; PMID:20101065; http://dx.doi.org/10.2146/ajhp090031
   PubMed Web of Science ®Google Scholar
• Jung ST, Kang TH, Kelton W, Georgiou G. Bypassing glycosylation: engineering aglycosylated full-length IgG antibodies for human therapy. Curr Opin Biotechnol 2011; 22:858-867; PMID:21420850; http://dx.doi.org/10.1016/j.copbio.2011.03.002
   PubMed Web of Science ®Google Scholar
• Wiczling P, Rosenzweig M, Vaickus L, Jusko WJ. Pharmacokinetics and pharmacodynamics of a chimeric/humanized anti-CD3 monoclonal antibody, otelixizumab (TRX4), in subjects with psoriasis and with type 1 diabetes mellitus. J Clin Pharmacol 2010; 50:494-506; PMID:19934031; http://dx.doi.org/10.1177/0091270009349376
   PubMed Web of Science ®Google Scholar
• Burton L, Gandhi R, Duke G, Paborji M. Use of microcalorimetry and its correlation with size exclusion chromatography for rapid screening of the physical stability of large pharmaceutical proteins in solution. Pharm Dev Technol 2007; 12:265-273; PMID:17613890; http://dx.doi.org/10.1080/10837450701212610
   PubMed Web of Science ®Google Scholar
• Wasylaschuk WR, Harmon PA, Wagner G, Harman AB, Templeton AC, Xu H, Reed RA. Evaluation of hydroperoxides in common pharmaceutical excipients. J Pharm Sci 2007; 96:106-116; PMID:16917844; http://dx.doi.org/10.1002/jps.20726
   PubMed Web of Science ®Google Scholar
• Torosantucci R, Schoneich C, Jiskoot W. Oxidation of therapeutic proteins and peptides: Structural and biological consequences. Pharm Res 2014; 31:541-553; PMID:24065593; http://dx.doi.org/10.1007/s11095-013-1199-9
   PubMed Web of Science ®Google Scholar
• Garber E, Demarest SJ. A broad range of Fab stabilities within a host of therapeutic IgGs. Biochem Biophys Res Commun 2007; 355:751-757; PMID:17321501; http://dx.doi.org/10.1016/j.bbrc.2007.02.042
   PubMed Web of Science ®Google Scholar
• Liu H, Bulseco GG, Sun J. Effect of posttranslational modifications on the thermal stability of a recombinant monoclonal antibody. Immunol Lett 2006; 106:144-153; PMID:16831470; http://dx.doi.org/10.1016/j.imlet.2006.05.011
   PubMed Web of Science ®Google Scholar
• Waterman KC, Adami RC. Accelerated aging: prediction of chemical stability of pharmaceuticals. Int J Pharm 2005; 293:101-125; PMID:15778049; http://dx.doi.org/10.1016/j.ijpharm.2004.12.013
   PubMed Web of Science ®Google Scholar
• Liu D, Ren D, Huang H, Dankberg J, Rosenfeld R, Cocco MJ, Li L, Brems DN, Remmele RL, Jr. Structure and stability changes of human IgG1 Fc as a consequence of methionine oxidation. Biochemistry 2008; 47:5088-5100; PMID:18407665; http://dx.doi.org/10.1021/bi702238b
   PubMed Web of Science ®Google Scholar
• Rabinow BE, Ding YS, Qin C, McHalsky ML, Schneider JH, Ashline KA, Shelbourn TL, Albrecht RM. Biomaterials with permanent hydrophilic surfaces and low protein adsorption properties. J Biomater Sci Polym Ed 1994; 6:91-109; PMID:7947476; http://dx.doi.org/10.1163/156856295X00788
   PubMed Web of Science ®Google Scholar
• Kraegen EW, Lazarus L, Meler H. Carrier solutions for low level intravenous insulin infusion. Br Med J 1975; 3:464-466; PMID:1156820; http://dx.doi.org/10.1136/bmj.3.5981.464
   PubMed Web of Science ®Google Scholar
• Page C, Dawson P, Woollacott D, Thorpe R, Mire-Sluis A. Development of a lyophilization formulation that preserves the biological activity of the platelet-inducing cytokine interleukin-11 at low concentrations. J Pharm Pharmacol 2000; 52:19-26; PMID:10716599; http://dx.doi.org/10.1211/0022357001773643
   PubMed Web of Science ®Google Scholar
• Suelter CH, DeLuca M. How to prevent losses of protein by adsorption to glass and plastic. Anal Biochem 1983; 135:112-119; PMID:6670734; http://dx.doi.org/10.1016/0003-2697(83)90738-8
   PubMed Web of Science ®Google Scholar
• Wasiewski W, Fasco MJ, Martin BM. Thrombin adsorption to surfaces and prevention with polyethylene glycol 6,000. Thrombosis Res 1976; 8:881-886; PMID:960059; http://dx.doi.org/10.1016/0049-3848(76)90017-7
   PubMed Web of Science ®Google Scholar
• Lee HJ, McAuley A, Schilke KF, McGuire J. Molecular origins of surfactant-mediated stabilization of protein drugs. Advanced Drug Delivery Reviews 2011; 63:1160-1171; PMID:21763375; http://dx.doi.org/10.1016/j.addr.2011.06.015
   PubMed Web of Science ®Google Scholar
• Kiese S, Papppenberger A, Friess W, Mahler HC. Shaken, not stirred: mechanical stress testing of an IgG1 antibody. J Pharm Sci 2008; 97:4347-4366; PMID:18240293; http://dx.doi.org/10.1002/jps.21328
   PubMed Web of Science ®Google Scholar
• Mahler HC, Muller R, Friess W, Delille A, Matheus S. Induction and analysis of aggregates in a liquid IgG1-antibody formulation. Eur J Pharm Biopharm 2005; 59:407-417; PMID:15760721; http://dx.doi.org/10.1016/j.ejpb.2004.12.004
   PubMed Web of Science ®Google Scholar
• Vidanovic D, Milic AJ, Stankovic M, Poprzen V. Effects of nonionic surfactants on the physical stability of immunoglobulin G in aqueous solution during mechanical agitation. Pharmazie 2003; 58:399-404; PMID:12857003
   PubMed Web of Science ®Google Scholar
• Duncan MR, Lee JM, Warchol MP. Influence of surfactants upon protein/peptide adsorption to glass and polypropylene. Int J Pharm 1995; 120:179-188; http://dx.doi.org/10.1016/0378-5173(94)00402-Q
   Web of Science ®Google Scholar
• Johnston TP. Adsorption of recombinant human granulocyte colony stimulating factor (rhG-CSF) to polyvinyl chloride, polypropylene, and glass: effect of solvent additives. PDA J Pharm Sci Technol 1996; 50:238-245; PMID:8810839
   PubMedGoogle Scholar
• Ha E, Wang W, Wang YJ. Peroxide formation in polysorbate 80 and protein stability. J Pharm Sci 2002; 91:2252-2264; PMID:12226852; http://dx.doi.org/10.1002/jps.10216
   PubMed Web of Science ®Google Scholar
• Wang W, Wang YJ, Wang DQ. Dual effects of Tween 80 on protein stability. Int J Pharm 2008; 347:31-38; PMID:17692480; http://dx.doi.org/10.1016/j.ijpharm.2007.06.042
   PubMed Web of Science ®Google Scholar
• Kerwin BA. Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways. J Pharm Sci 2008; 97:2924-2935; PMID:17973307; http://dx.doi.org/10.1002/jps.21190
   PubMed Web of Science ®Google Scholar
• Usami A, Ohtsu A, Takahama S, Fujii T. The effect of pH, hydrogen peroxide and temperature on the stability of human monoclonal antibody. J Pharm Biomed Anal 1996; 14:1133-1140; PMID:8818025; http://dx.doi.org/10.1016/S0731-7085(96)01721-9
   PubMed Web of Science ®Google Scholar
• Lowe D, Dudgeon K, Rouet R, Schofield P, Jermutus L, Christ D. Aggregation, stability, and formulation of human antibody therapeutics. Adv Protein Chem Struct Biol 2011; 84:41-61; PMID:21846562; http://dx.doi.org/10.1016/B978-0-12-386483-3.00004-5
   PubMed Web of Science ®Google Scholar
• Lahlou A, Blanchet B, Carvalho M, Paul M, Astier A. Mechanically-induced aggregation of the monoclonal antibody cetuximab. Ann Pharm Fr 2009; 67:340-352; PMID:19695370; http://dx.doi.org/10.1016/j.pharma.2009.05.008
   PubMedGoogle Scholar
• Ji JA, Zhang B, Cheng W, Wang YJ. Methionine, tryptophan, and histidine oxidation in a model protein, PTH: mechanisms and stabilization. J Pharm Sci 2009; 98:4485-4500; PMID:19455640; http://dx.doi.org/10.1002/jps.21746
   PubMed Web of Science ®Google Scholar
• Chumsae C, Gaza-Bulseco G, Sun J, Liu H. Comparison of methionine oxidation in thermal stability and chemically stressed samples of a fully human monoclonal antibody. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 850:285-294; PMID:17182291; http://dx.doi.org/10.1016/j.jchromb.2006.11.050
   PubMed Web of Science ®Google Scholar
• Bertolotti-Ciarlet A, Wang W, Lownes R, Pristatsky P, Fang Y, McKelvey T, Li Y, Li Y, Drummond J, Prueksaritanont T, Vlasak J. Impact of methionine oxidation on the binding of human IgG1 to Fc Rn and Fc gamma receptors. Mol Immunol 2009; 46:1878-1882; PMID:19269032; http://dx.doi.org/10.1016/j.molimm.2009.02.002
   PubMed Web of Science ®Google Scholar
• Liu H, Gaza-Bulseco G, Zhou L. Mass spectrometry analysis of photo-induced methionine oxidation of a recombinant human monoclonal antibody. J Am Soc Mass Spectrom 2009; 20:525-528; PMID:19103498; http://dx.doi.org/10.1016/j.jasms.2008.11.011
   PubMed Web of Science ®Google Scholar
• Margiloff L, Chaplia L, Chow A, Singhal PC, Mattana J. Metal-catalyzed oxidation of immunoglobulin G impairs Fc receptor-mediated binding to macrophages. Free Radic Biol Med 1998; 25:780-785; PMID:9823543; http://dx.doi.org/10.1016/S0891-5849(98)00130-0
   PubMed Web of Science ®Google Scholar
• Kayser V, Chennamsetty N, Voynov V, Forrer K, Helk B, Trout BL. Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies. Biotechnol J 2011; 6:38-44; PMID:20949542; http://dx.doi.org/10.1002/biot.201000091
   PubMed Web of Science ®Google Scholar
• Wen J, Jiang Y, Nahri L. Effect of carbohydrate on thermal stability of antibodies. Am Pharm Rev 2008; 11:98-104; http://dx.doi.org/10.1002/jps.3080110209
   Google Scholar
• Zheng K, Bantog C, Bayer R. The impact of glycosylation on monoclonal antibody conformation and stability. MAbs 2011; 3:568-576; PMID:22123061; http://dx.doi.org/10.4161/mabs.3.6.17922
   PubMed Web of Science ®Google Scholar
• Liu H, Gaza-Bulseco G, Xiang T, Chumsae C. Structural effect of deglycosylation and methionine oxidation on a recombinant monoclonal antibody. Mol Immunol 2008; 45:701-708; PMID:17719636; http://dx.doi.org/10.1016/j.molimm.2007.07.012
   PubMed Web of Science ®Google Scholar
• Waterman KC, Adami RC, Alsante KM, Hong J, Landis MS, Lombardo F, Roberts CJ. Stabilization of pharmaceuticals to oxidative degradation. Pharm Dev Technol 2002; 7:1-32; PMID:11852692; http://dx.doi.org/10.1081/PDT-120002237
   PubMed Web of Science ®Google Scholar
• Lam XM, Yang JY, Cleland JL. Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2. J Pharm Sci 1997; 86:1250-1255; PMID:9383735; http://dx.doi.org/10.1021/js970143s
   PubMed Web of Science ®Google Scholar
• Reyes N, Ruiz L, Aroche K, Geronimo H, Brito O, Hardy E. Stability of Ala 125 recombinant human interleukin-2 in solution. J Pharm Pharmacol 2005; 57:31-37; PMID:15638990; http://dx.doi.org/10.1211/0022357055182
   PubMed Web of Science ®Google Scholar
• Yin J, Chu JW, Ricci MS, Brems DN, Wang DI, Trout BL. Effects of antioxidants on the hydrogen peroxide-mediated oxidation of methionine residues in granulocyte colony-stimulating factor and human parathyroid hormone fragment 13-34. Pharm Res 2004; 21:2377-2383; PMID:15648272; http://dx.doi.org/10.1007/s11095-004-7692-4
   PubMed Web of Science ®Google Scholar
• Knepp VM, Whatley JL, Muchnik A, Calderwood TS. Identification of antioxidants for prevention of peroxide-mediated oxidation of recombinant human ciliary neurotrophic factor and recombinant human nerve growth factor. PDA J Pharm Sci Technol 1996; 50:163-171; PMID:8696780
   PubMedGoogle Scholar
• Sosabowski JK, Lee M, Dekker BA, Simmons BP, Singh S, Beresford H, Hagan SA, McKenzie AJ, Mather SJ, Watson SA. Formulation development and manufacturing of a gastrin/CCK-2 receptor targeting peptide as an intermediate drug product for a clinical imaging study. Eur J Pharm Sci 2007; 31:102-111; PMID:17387005; http://dx.doi.org/10.1016/j.ejps.2007.02.007
   PubMed Web of Science ®Google Scholar
• Yin J, Chu JW, Ricci MS, Brems DN, Wang DI, Trout BL. Effects of excipients on the hydrogen peroxide-induced oxidation of methionine residues in granulocyte colony-stimulating factor. Pharm Res 2005; 22:141-147; PMID:15771240; http://dx.doi.org/10.1007/s11095-004-9019-x
   PubMed Web of Science ®Google Scholar